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Abstract
● AIM: To evaluate and compare the quality of life of 
patients submitted to XEN® implant or trabeculectomy and 
the relationship with potentially involved variables.
● METHODS: A cross-sectional study of patients with 
advanced open-angle glaucoma who underwent implantation 
of XEN® (group 1) and trabeculectomy (group 2) between 
October 2015 and February 2017. The studied variables were: 
age, gender, follow-up time, need of topical anti-hypertensive 
therapy, visual acuity and intraocular pressure (IOP). The 
quantification of the quality of life was attained through 
the Glaucoma Symptom Scale (GSS) questionnaire. 
● RESULTS: Totally 34 eyes (34 patients) were included, 
17 in each group. The mean GSS scores for group 1 were 
42.6±6.8 (median, 47; p25, 36.5; p75, 48.5) and for group 2 
it was 41.6±7.0 (median, 43; p25, 36.5; p75, 47.0; P=0.34). 
There was a strong negative correlation between the need 
for topical anti-hypertensive drugs and the GSS result in 
both groups (r=-0.88, P<0.01, r=-0.59, P=0.01, respectively) 
and a moderate negative correlation with IOP in group 1 
(r=-0.50, P=0.03).
● CONCLUSION: The analysis demonstrates the non-
inferiority of medium-term quality of life of one group in 
relation to the other (XEN® implant and trabeculectomy). 
The number of topical anti-hypertensive drugs and IOP 
negatively influenced the quality of life.
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INTRODUCTION
T he ophthalmologist must always bear in mind the influence that both diagnosis and treatment of glaucoma 
have on the patient’s quality of life[1]. There are several studies 
on the impact of glaucoma on quality of life, however the 
effect of treatment on the routine of these patients has been 
poorly studied[2-4]. Most clinical trials have evaluated the 
success of treatments with objective clinical measures[5-8], 
and only one randomized multicenter clinical trial has been 
conducted so far to assess the impact of glaucoma treatment in 
quality of life[9].
The Glaucoma Symptom Scale (GSS) questionnaire is a 
modified version of the “Ocular Hypertension Treatment 
Study 10-item Symptom Checklist”. It is specific for 
patients with glaucoma and it quantifies common symptoms 
present in patients with this condition. It is a simple, short, 
comprehensive test consisting of ten questions that include two 
dimensions: non-visual ocular symptoms (burning/smarting/
stinging, tearing, soreness/tiredness, itching, foreign body 
sensation, dryness) and visual symptoms (blurry/dim vision, 
hard to see in daylight, hard to see in darkness, halos around 
lights). Allows to apply the test to each individual eye (result of 
0-50) or bilaterally (result of 0-100). It has been validated for 
use in clinical practice and in research to quantify symptoms 
in patients with glaucoma, namely to assess the effect of the 
disease and its treatments on the populations[10].
Trabeculectomy is considered the gold standard approach 
concerning the surgical treatment of glaucoma, since it allows 
an effective reduction of intraocular pressure (IOP) in most 
cases. However, the postoperative period of this surgery may 
be associated with complications, sometimes compromising 
the patient’s vision[11-12].
The implant of the XEN45® Gel Stent Glaucoma Treatment 
System (Allergan, Irvine, CA) is considered a minimally 
invasive surgical procedure and it was introduced in 2014 in 
Europe for treatment of open angle glaucoma refractory to 
medical therapy[13]. It is inserted by a microincision into the 
cornea and creates a drainage fistula for aqueous humor to 
the subconjunctival space[8,14]. It is a less traumatic procedure 
than trabeculectomy and associated with a lower incidence of 
serious complications, which could mean a faster recovery and 
a lower impact on quality of life[15-16].
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The primary aim of this study was to compare the medium-
term quality of life of patients with advanced open 
angle glaucoma who underwent XEN® implantation or 
trabeculectomy and to secondarily investigate the relationship 
with potentially involved variables.
SUBJECTS AND METHODS
The authors conducted a comparative cross-sectional study 
in agreement with the Declaration of Helsinki for research 
involving humans. At our tertiary institution of ophthalmology, 
a sample of patients with open angle glaucoma who underwent 
XEN® implantation and trabeculectomy, between October 
2015 and February 2017, were recruited. All patients to 
whom the XEN® implant was placed in the specified period 
were chosen for group 1. For group 2, a random selection of 
patients submitted to trabeculectomy in the same period was 
performed, in order to match the number of patients in group 
1. All patients (groups 1 and 2) had advanced open angle 
glaucoma, uncontrolled with anti-hypertensive therapy, and the 
conjunctiva was satisfactorily preserved in both groups.
Patients submitted to combined surgery, prior ipsilateral eye 
surgery, diagnosed with ocular surface disease, cognitive 
or auditory impairment were excluded from the study. The 
following data were analyzed as: age, gender, postoperative 
follow-up time, topical anti-hypertensive therapy in the 
postoperative period, last record of best-corrected visual acuity 
(BCVA) and IOP. Patients were contacted via telephone and, 
after their verbal consent to participate in the study, answered 
the GSS questionnaire in relation to the operated eye. The 
patient was asked, for each of the 10 symptoms addressed in 
the questionnaire, whether this was a problem or not in the 
last 4wk and, if so, what was the degree of discomfort. The 
answers were converted into numerical values, according to the 
questionnaire [absent -4, present 0 to -3 (very uncomfortable 
0, some discomfort -1, little inconvenience -2, did not cause 
discomfort -3)]. At the sum of the individual values, 10 values 
were always added and the final GSS score between 0 and 50 
was obtained.
Statistical analysis was performed using SPSS software 
version 23.0 (SPSS, Chicago, USA). Comparison of the 
GSS results between groups was performed using the Mann-
Whitney test and Spearman’s correlation was used for the 
correlation analysis of the variables. The P value less than 0.05 
was considered statistically significant.
RESULTS
The study included 34 eyes from 34 patients, 17 eyes in 
each group. All patients selected to participate in the study 
accepted to respond to the survey. Regarding mean age, group 
1 presented 69.9±12.4y and group 2 presented 67.3±15.4y 
(P>0.05). The characterization of patients in both groups is 
shown in Table 1.
The mean GSS score for group 1 was 42.6±6.8 (median, 47; 
p25, 36.5; p75, 48.5) and for group 2 it was 41.6±7.0 (median, 
43; p25, 36.5; p75, 47; P=0.34). There were no statistically 
significant differences between groups when symptoms were 
compared alone or in terms of visual and non-visual symptoms 
(Table 2).
The analysis of the relationship between the results of the GSS 
questionnaire and the various variables revealed a strongly 
negative correlation between the administration of topical anti-
hypertensive drug and the GSS result in both study groups 
(r=-0.88, P<0.01 and r=-0.59, P=0.01, respectively). There 
was a moderate negative correlation between GSS and IOP in 
group 1 (r=-0.50, P=0.03). No significant correlations were 
established with age, postoperative follow-up time and BCVA 
(Table 3).
Table 1 Description of patients in groups 1 and 2
 Patients data Group 1 (XEN®)
Group 2 
(Trabeculectomy) P
Patients (n) 17 17
Eyes (n) 17 17
Age >0.05
  Mean 69.9 67.3
  Median 74 74
  Min 47 44
  Max 93 86
  SD 12.4 15.4
Gender, n (%)
   M 10 (58.8) 13 (76.4)
   F 7 (41.2) 4 (23.6)
Topical anti-hypertensive drugs required, n (%)
  0 9 (52.9) 7 (41.2)
  1 2 (11.8) 3 (17.6)
  2 4 (23.5) 1 (5.9)
  3 2 (11.8) 5 (29.4)
  4 0 (0) 1 (5.9)
Post-operative follow-up time (mo) >0.05
  Mean 15.5 15.4
  Median 12 15
  Min 8 8
  Max 24 24
  SD 6.5 5.2
BCVA (logMAR) >0.05
  Mean 0.2 0.2
  Median 0.1 0.2
  Min 0 0
  Max 1.3 1.3
  SD 0.4 0.2
IOP (mm Hg) >0.05
  Mean 14.8 13.9
  Median 14 14
  Min 6 10
  Max 30 30
  SD 6.2 4.7
Min: Minimum; Max: Maximum; SD: Standard deviation; BCVA: 
Best-corrected visual acuity; IOP: Intraocular pressure.
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DISCUSSION
The impact of glaucoma diagnosis and therapy on the patient’s 
quality of life still lacks practical objective measures. To 
the best of our knowledge, this is the first study to evaluate 
the quality of life in patients submitted to XEN® device 
implantation. The GSS questionnaire was applied in order to 
determine whether there were recognized differences in the 
effect of two different surgical treatments in quality of life of 
patients with glaucoma.
Although other questionnaires such as the NEI VFQ-25 were 
more frequently cited[1,17-20], the GSS questionnaire was chosen 
because it is simpler and shorter to apply, with good patient 
adherence, and because it includes non-visual symptoms in the 
comparison of the results of the two types of intervention performed.
Likewise, there are no published studies comparing the 
quality of life of this new procedure with trabeculectomy[11]. 
The analysis demonstrated the non-inferiority of quality of 
life of one group in relation to the other for the presence 
and degree of discomfort of non-visual and visual ocular 
symptoms. The surgical technique underlying XEN® device 
implantation and trabeculectomy might suggest less impact 
on ocular symptomatology in the first group, but this was not 
observed in this study. The advantages of a minimally invasive 
surgery, such as the XEN® implant, regarding ocular surface 
symptomatology may be concentrated mainly in the immediate 
postoperative period and this was not included in this analysis. 
Similar results were obtained by Pahlitzsch et al[20], when 
comparing the quality of life 6-months post trabeculectomy, 
iStent® and Trabectome® procedure. In this study, the authors 
chose to standardize follow-up time between the two groups, 
and there was no significant difference between the two 
groups. Further studies may compare results in the immediate 
postoperative period or different stages in each group 
according to the clinical presentation, namely with the features 
of the conjunctiva after trabeculectomy. The number of topical 
antihypertensive drugs strongly influenced the quality of life in 
both groups, possibly due to the symptomatology of the ocular 
surface that can develop collaterally[21].
Table 2 GSS results (general results, by symptom and by non-visual and visual symptoms) and comparison between the two groups
Results Group 1 (XEN®) Group 2 (trabeculectomy) P
GSS score 0.34
  Mean 42.6 41.6
  Min 30 22
  Max 50 49
  SD 6.8 7.0
  Median 47 43
  P25 36.5 36.5
  P75 48.5 47.0
Symptom (mean) 
  Burning/smarting/stinging 3.1 2.7 0.20
  Tearing 3.0 2.7 0.26
  Dryness 3.6 4.0 0.06
  Itching 3.5 3.6 0.36
  Soreness/tiredness 3.1 3.1 0.45
  Foreign body sensation 3.5 3.4 0.44
  Blurry/dim vision 3.2 2.8 0.15
  Hard to see in daylight 3.1 3.0 0.40
  Hard to see in darkness 3.6 3.5 0.30
  Halos around lights 3.5 2.9 0.07
Non-visual symptoms (mean) 19.8 19.5 0.43
Visual symptoms (mean) 13.5 12.1 0.16
GSS: Glaucoma Symptom Scale; Min: Minimum; Max: Maximum; SD: Standard deviation.
Table 3 Study of the relationship between the variables and the GSS result
Studied variables
Group 1 (XEN®) Group 2 (trabeculectomy)
Correlation coefficient P Correlation coefficient P
Age 0.13 0.62 0.19 0.46
Number of topical anti-hypertensive drug required -0.88 <0.01 -0.59 0.01
Postoperative follow-up time -0.37 0.14 -0.14 0.59
BCVA -0.11 0.72 0.01 0.97
IOP -0.50 0.03 -0.05 0.85
BCVA: Best-corrected visual acuity; IOP: Intraocular pressure.
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There was also a moderate negative relationship between 
IOP and the outcome of the score in group 1, which may be 
related to the need for instillation of anti-hypertensive drops 
and to manipulation of the filtering bleb. The quality of life 
analysis performed by Guedes et al[22], who compared groups 
at different stages of glaucoma and with different therapeutic 
strategies, found that early glaucoma was associated with 
poorer quality of life, probably due to the psychological impact 
of the diagnosis of the disease. In the moderate and advanced 
phases, the quality of life did not differ significantly between 
the groups with medical and surgical therapy.
There are some limitations in this study, such as the fact that 
it is a small sample, but it is important to note that our center 
was the first at national level to insert the XEN® device and 
the reported results resemble to those patients. Moreover, the 
results may be influenced according to the status of patients 
such as vision or visual field in the fellow eye. This is mainly 
a pioneering study, comparing the results of a classic surgical 
technique (trabeculectomy) with the results of a recently 
marketed device (XEN®), most properly the first cases that 
matched the criteria for the study. It will be important to 
undertake further studies with a larger number of patients and 
applying the survey prior to surgery and regularly thereafter.
The use of this type of questionnaire is important in clinical 
practice because it allows the monitoring of chronic ocular 
symptoms objectively. The applicability of GSS in research 
is validated and may be an important tool in the comparative 
study of different treatments, medical or surgical.
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